/

Empresas

Am

No verificado

Amgen

Sobre qué escribimos

BiotecnologíaFarmacéuticaIndustriaSaludSanidad

3 Comunicados de prensa

Ver todos los comunicados de prensa

07/05/2025

Industria

Ciencia

Biotecnología

Farmacéutica

Óptica

Salud

Medicina - Varios

Amgen’s TEPEZZA®▼ (teprotumumab) Granted Marketing Authorisation as the First Targeted Treatment Specifically for Adults With Moderate-to-severe Thyroid Eye Disease (TED) in the United Kingdom

Fuente

Editor

1.00

0

Press Release cover image

29/01/2025

Farmacéutica

Sanidad

Biología

EUROPEAN COMMISSION APPROVES BLINCYTO® IN PHILADELPHIA CHROMOSOME-NEGATIVE CD19-POSITIVE B-CELL PRECURSOR ACUTE LYMPHOBLASTIC LEUKEMIA IN THE CONSOLIDATION PHASE

Fuente

Editor

1.00

0

06/01/2025

Industria

Ciencia

Biotecnología

Farmacéutica

Oncología

Salud

Sanidad

Amgen’s IMDYLLTRA®▼ (tarlatamab) Granted a Conditional Marketing Authorisation for Third-Line Treatment of Extensive-Stage Small Cell Lung Cancer in the United Kingdom

Fuente

Editor

1.00

0

Seguidores

0

Compatibilidad

0